Fujifilm Diosynth Biotechnologies, Piramal Announce Strategic Alliance

Fujifilm Diosynth Biotechnologies has announced it has entered into a strategic alliance with Piramal Healthcare UK, whereby the two parties will offer the seamless contract development and manufacture of antibody drug conjugates (ADCs), a growing niche in the development of biopharmaceuticals.

Fujifilm Diosynth Biotechnologies is one of the world's leading providers of contract development and manufacturing services for biopharmaceuticals, whilst Piramal is a world leader in antibody drug conjugation.

For Fujifilm Diosynth Biotechnologies, this is part of an ongoing programme to expand its offering in mammalian-based biopharmaceuticals. The company recently announced an expansion of its cGMP manufacturing facilities at both its RTP, USA and Billingham, UK sites.